ImmuCell (ICCC) Stock Price

ImmuCell Price

NASDAQ·CLOSED
11.15USD+0.02 (+0.18 %)
Market closed

Revenue has compounded at 9.2% per year over the past 19 years to 26.49 M USD. Earnings per share have declined at 6.2% per year over the last 11 years. ImmuCell's net margin stands at -8.1%, down from -6.6% several years earlier. The stock trades about 145% above its 52-week low.

ImmuCell stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of ImmuCell over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ImmuCell stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ImmuCell's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

ImmuCell Stock Price History
DateImmuCell Price
7/20/202611.15 USD
7/17/202611.13 USD
7/16/202611.13 USD
7/15/202610.73 USD
7/14/202611.72 USD
7/13/202611.00 USD
7/10/202610.89 USD
7/9/202611.45 USD
7/8/202610.47 USD
7/7/202610.34 USD
7/6/202610.14 USD
7/2/202610.29 USD
7/1/202611.00 USD
6/30/202610.05 USD
6/29/20269.91 USD
6/26/20269.79 USD
6/25/20269.89 USD
6/24/20269.79 USD
6/23/20269.86 USD
6/22/20269.65 USD
6/18/20269.49 USD
6/17/20269.39 USD
6/16/20269.38 USD
6/15/20269.53 USD
6/12/20269.68 USD
6/11/20269.74 USD
6/10/20269.67 USD
6/9/20269.77 USD
6/8/20269.70 USD
6/5/20269.61 USD
6/4/20269.87 USD
6/3/202610.05 USD
6/2/20269.79 USD
6/1/20269.67 USD
5/29/202610.24 USD
5/28/20269.90 USD
5/27/202610.63 USD
5/26/202610.50 USD
5/22/202610.12 USD
5/21/202610.01 USD
5/20/20269.88 USD
5/19/202610.20 USD
5/18/20269.91 USD
5/15/20268.92 USD
5/14/20268.26 USD
5/13/20268.36 USD
5/12/20268.38 USD
5/11/20268.45 USD
5/8/20268.05 USD
5/7/20268.47 USD
5/6/20268.66 USD
5/5/20268.89 USD
5/4/20268.72 USD
5/1/20268.73 USD
4/30/20268.46 USD
4/29/20268.44 USD
4/28/20268.35 USD
4/27/20268.25 USD
4/24/20268.36 USD
4/23/20267.98 USD
4/22/20267.82 USD
4/21/20267.72 USD
4/20/20268.02 USD
4/17/20267.98 USD
4/16/20267.54 USD
4/15/20267.60 USD
4/14/20267.73 USD
4/13/20267.11 USD
4/10/20267.08 USD
4/9/20267.19 USD
4/8/20266.38 USD
4/7/20266.60 USD
4/6/20266.61 USD
4/2/20266.44 USD
4/1/20266.35 USD
3/31/20266.33 USD
3/30/20266.43 USD
3/27/20266.52 USD
3/26/20266.53 USD
3/25/20266.44 USD
3/24/20266.39 USD
3/23/20266.41 USD
3/20/20266.07 USD
3/19/20266.15 USD
3/18/20266.04 USD
3/17/20266.05 USD
3/16/20266.39 USD
3/13/20266.37 USD
3/12/20266.63 USD
3/11/20266.65 USD
3/10/20266.63 USD
3/9/20266.48 USD
3/6/20266.60 USD
3/5/20266.35 USD
3/4/20266.46 USD
3/3/20266.40 USD
3/2/20266.54 USD
2/27/20266.57 USD
2/26/20266.55 USD
2/25/20266.57 USD
2/24/20266.56 USD
2/23/20266.40 USD
2/20/20266.42 USD
2/19/20266.67 USD
2/18/20266.48 USD
2/17/20266.24 USD
2/13/20266.60 USD
2/12/20266.62 USD
2/11/20266.49 USD
2/10/20266.63 USD
2/9/20266.64 USD
2/6/20266.24 USD
2/5/20266.11 USD
2/4/20266.07 USD
2/3/20265.84 USD
2/2/20266.11 USD
1/30/20266.02 USD
1/29/20266.04 USD
1/28/20266.37 USD
1/27/20266.27 USD
1/26/20266.31 USD
1/23/20266.26 USD
1/22/20266.56 USD
1/21/20266.80 USD
1/20/20266.52 USD
1/16/20266.36 USD
1/15/20266.64 USD
1/14/20266.62 USD
1/13/20266.65 USD
1/12/20266.67 USD
1/9/20266.50 USD
1/8/20266.57 USD
1/7/20266.24 USD
1/6/20266.35 USD
1/5/20266.05 USD
1/2/20265.92 USD
12/31/20256.15 USD
12/30/20256.11 USD
12/29/20256.15 USD
12/26/20256.12 USD
12/24/20255.80 USD
12/23/20255.82 USD
12/22/20255.90 USD
12/19/20255.97 USD
12/18/20256.14 USD
12/17/20256.09 USD
12/16/20256.04 USD
12/15/20256.14 USD
12/12/20256.21 USD
12/11/20256.07 USD
12/10/20255.87 USD
12/9/20255.57 USD
12/8/20255.48 USD
12/5/20255.64 USD
12/4/20255.21 USD
12/3/20255.25 USD
12/2/20255.00 USD
12/1/20254.74 USD
11/28/20254.84 USD
11/26/20254.80 USD
11/25/20254.68 USD
11/24/20254.72 USD
11/21/20254.68 USD
11/20/20254.60 USD
11/19/20254.74 USD
11/18/20254.56 USD
11/17/20254.91 USD
11/14/20255.40 USD
11/13/20256.05 USD
11/12/20256.13 USD
11/11/20256.27 USD
11/10/20256.08 USD
11/7/20256.10 USD
11/6/20256.31 USD
11/5/20256.30 USD
11/4/20256.00 USD
11/3/20256.21 USD
10/31/20256.24 USD
10/30/20256.09 USD
10/29/20256.03 USD
10/28/20256.16 USD
10/27/20256.24 USD
10/24/20256.08 USD
10/23/20256.06 USD
10/22/20256.49 USD
10/21/20256.13 USD
10/20/20256.16 USD
10/17/20256.06 USD
10/16/20256.25 USD
10/15/20256.63 USD
10/14/20256.52 USD
10/13/20256.58 USD
10/10/20256.80 USD
10/9/20256.72 USD
10/8/20256.59 USD
10/7/20256.45 USD
10/6/20256.35 USD
10/3/20256.31 USD
10/2/20256.55 USD
10/1/20256.60 USD
9/30/20256.25 USD
9/29/20256.18 USD
9/26/20256.03 USD
9/25/20256.05 USD
9/24/20256.06 USD
9/23/20256.20 USD
9/22/20256.25 USD
9/19/20255.96 USD
9/18/20255.66 USD
9/17/20255.65 USD
9/16/20255.90 USD
9/15/20255.95 USD
9/12/20255.92 USD
9/11/20256.13 USD
9/10/20256.16 USD
9/9/20256.16 USD
9/8/20256.56 USD
9/5/20256.33 USD
9/4/20256.52 USD
9/3/20256.53 USD
9/2/20256.18 USD
8/29/20256.40 USD
8/28/20256.12 USD
8/27/20256.10 USD
8/26/20256.25 USD
8/25/20256.09 USD
8/22/20256.09 USD
8/21/20255.98 USD
8/20/20256.04 USD
8/19/20255.90 USD
8/18/20256.11 USD
8/15/20256.10 USD
8/14/20256.72 USD
8/13/20256.53 USD
8/12/20256.65 USD
8/11/20256.66 USD
8/8/20256.66 USD
8/7/20256.14 USD
8/6/20256.18 USD
8/5/20256.19 USD
8/4/20256.25 USD
8/1/20256.00 USD
7/31/20256.37 USD
7/30/20256.46 USD
7/29/20256.49 USD
7/28/20256.63 USD
7/25/20256.61 USD
7/24/20256.76 USD
7/23/20256.95 USD
7/22/20256.83 USD
7/21/20256.82 USD
Access this data via the Eulerpool API
Get Free API Key

ImmuCell Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
10.43 M USD
-240,000.00 USD
-170,000.00 USD
Jan 1, 2018
10.99 M USD
-2.15 M USD
-2.32 M USD
Jan 1, 2019
13.72 M USD
-950,000.00 USD
-1.30 M USD
Jan 1, 2020
15.34 M USD
-1.38 M USD
-1.02 M USD
Jan 1, 2021
19.24 M USD
260,000.00 USD
-80,000.00 USD
Jan 1, 2022
18.57 M USD
-2.30 M USD
-2.49 M USD
Jan 1, 2023
17.47 M USD
-5.75 M USD
-5.77 M USD
Jan 1, 2024
26.49 M USD
-1.64 M USD
-2.16 M USD

ImmuCell Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 21, 2026, 3:36 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2009201020112012201320142015201620172018201920202021202220232024
4.004.005.005.006.007.0010.009.0010.0010.0013.0015.0019.0018.0017.0026.00
––25.00–20.0016.6742.86-10.0011.11–30.0015.3826.67-5.26-5.5652.94
50.0050.0040.0060.0050.0057.1460.0055.5650.0050.0046.1540.0042.1138.8917.6526.92
2.002.002.003.003.004.006.005.005.005.006.006.008.007.003.007.00
––––––2.00––-2.00–-1.00–-2.00-5.00-1.00
––––––20.00––-20.00–-6.67–-11.11-29.41-3.85
––––––1.00––-2.00-1.00-1.00–-2.00-5.00-2.00
––––––––––-50.00–––150.00-60.00
2.962.972.983.113.093.033.044.344.955.496.827.217.597.757.758.17
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales ImmuCell generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ImmuCell retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ImmuCell's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares ImmuCell has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ImmuCell's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ImmuCell stock margins

The ImmuCell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ImmuCell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ImmuCell.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
50.05 %
-2.30 %
-1.63 %
Jan 1, 2018
47.22 %
-19.56 %
-21.11 %
Jan 1, 2019
49.13 %
-6.92 %
-9.48 %
Jan 1, 2020
44.72 %
-9.00 %
-6.65 %
Jan 1, 2021
45.01 %
1.35 %
-0.42 %
Jan 1, 2022
41.20 %
-12.39 %
-13.41 %
Jan 1, 2023
22.15 %
-32.90 %
-33.05 %
Jan 1, 2024
29.97 %
-6.19 %
-8.14 %

ImmuCell Stock Revenue, EBIT, Earnings per Share

The ImmuCell earnings per share therefore indicates how much revenue ImmuCell has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
2.11 USD
-0.05 USD
-0.03 USD
Jan 1, 2018
2.00 USD
-0.39 USD
-0.42 USD
Jan 1, 2019
2.01 USD
-0.14 USD
-0.19 USD
Jan 1, 2020
2.13 USD
-0.19 USD
-0.14 USD
Jan 1, 2021
2.53 USD
0.03 USD
-0.01 USD
Jan 1, 2022
2.40 USD
-0.30 USD
-0.32 USD
Jan 1, 2023
2.26 USD
-0.74 USD
-0.75 USD
Jan 1, 2024
3.24 USD
-0.20 USD
-0.26 USD

ImmuCell business model & stock analysis

ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock.

ImmuCell SWOT Analysis

Strengths

ImmuCell Corp has several strengths that contribute to its competitive advantage in the market:

  • Strong brand reputation in the animal health industry.
  • Unique and innovative product offerings that address specific customer needs.
  • Extensive research and development capabilities, allowing for continuous improvement and product enhancements.
  • Efficient manufacturing processes that ensure high-quality products and cost-effectiveness.
  • Experienced management team with industry expertise and a track record of success.

Weaknesses

Despite its strengths, ImmuCell Corp also faces certain weaknesses that can hinder its growth and performance:

  • Reliance on a limited number of key customers for a significant portion of its revenue.
  • Vulnerability to pricing pressures due to intense competition in the market.
  • Limited international presence, potentially missing out on global market opportunities.
  • Dependence on a few key suppliers for essential raw materials.
  • Legal and regulatory challenges that may impact product development and approval processes.

Opportunities

ImmuCell Corp can explore several opportunities to further expand its business and improve market positioning:

  • Increasing demand for animal health products, driven by a growing pet population and rising awareness of animal welfare.
  • Expansion into international markets to tap into emerging economies and untapped customer segments.
  • Strategic partnerships or collaborations with complementary companies to diversify product offerings and reach new markets.
  • Ongoing advancements in biotechnology and healthcare, presenting possibilities for developing innovative solutions.
  • Evolving regulatory landscape that may create favorable conditions for product development and marketing.

Threats

ImmuCell Corp should be mindful of the following threats that could impact its business operations and profitability:

  • Intense competition from existing and emerging players in the animal health industry.
  • Fluctuating raw material prices, potentially affecting production costs and profit margins.
  • Changing consumer preferences and market trends that may require constant adaptation and product evolution.
  • Economic downturns or recessions that could lead to reduced customer spending on non-essential products.
  • Stringent regulations and compliance requirements, posing challenges to product development and marketing efforts.

ImmuCell Segments

ImmuCell Revenue by Segment (1/2)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
First Defense product line
Other animal health
Other Product Services
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD

ImmuCell Revenue by Segment (2/2)

  • Max

Scours
Mastitis
Details
Date
Scours
Mastitis
Jan 1, 2023
17.29 M USD
177,736.00 USD

ImmuCell Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
Other States
Details
Date
United States
Other States
Jan 1, 2018
9.56 M USD
1.43 M USD

ImmuCell Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

ImmuCell historical P/E ratio, EBIT multiple, and P/S ratio

ImmuCell annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

ImmuCell shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
4.95 M Stocks
Jan 1, 2018
5.49 M Stocks
Jan 1, 2019
6.82 M Stocks
Jan 1, 2020
7.21 M Stocks
Jan 1, 2021
7.59 M Stocks
Jan 1, 2022
7.75 M Stocks
Jan 1, 2023
7.75 M Stocks
Jan 1, 2024
8.17 M Stocks

ImmuCell stock splits

In ImmuCell's history, there have been no stock splits.
Price targets and forecasts for ImmuCell are not yet available.

ImmuCell Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
2/22/2021-0.04USD4.06 MUSD2020 Q4
11/12/2020-0.08USD3.32 MUSD2020 Q3
8/12/2020-0.10USD3.04 MUSD2020 Q2

ImmuCell shareholder structure

% Name
7.11623%
Pessin (Norman H)
Pessin (Norman H)
5.67959%
Rothschild (Jonathan E)
Rothschild (Jonathan E)
5.54981%
SRK Capital, LLC
SRK Capital, LLC
5.12286%
Knudsen (Ejnar A III)
Knudsen (Ejnar A III)
4.43999%
Pessin (Sandra F)
Pessin (Sandra F)
3.41107%
The Vanguard Group, Inc.
The Vanguard Group, Inc.

ImmuCell Executives and Management Board

MB

Mr. Michael Brigham

(64)

President, Chief Executive Officer, Treasurer, Secretary, Director · since 1991

Compensation392,609.00 USD
BB

Ms. Bobbi Brockmann

(49)

Vice President - Sales and Marketing, Director · since 2015

Compensation364,403.00 USD
DT

Dr. David Tomsche

(68)

Independent Non-Executive Chairman of the Board

Compensation56,300.00 USD
BG

Mr. Bryan Gathagan

(57)

Independent Director

Compensation45,800.00 USD
SR

Mr. Steven Rosgen

(59)

Independent Director

Compensation45,800.00 USD

ImmuCell Supply Chain

ImmuCell Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#Name1M3M6M1Y2YTrend
1
Patterson Companies
0.06
0.18
0.44
0.34
0.69
2
AmerisourceBergen
-0.09
0.23
0.36
-0.30
0.50

Frequently asked questions about ImmuCell

ImmuCell Corp operates as a biotechnology company, focusing on the development and commercialization of products that improve the health and productivity of dairy and beef cattle. The company's business model revolves around providing innovative animal health solutions, such as First Defense® for newborn calves, which helps strengthen their immune system and prevent diseases. ImmuCell Corp also offers Mast Out®, an FDA-approved treatment for mastitis in lactating dairy cows. Through its dedication to science-driven research and development, ImmuCell Corp aims to enhance animal well-being, increase farmers' efficiency, and ultimately contribute to a sustainable agriculture industry.

All fundamentals and in-depth analysis of ImmuCell

Our stock analysis for ImmuCell stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmuCell. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

ImmuCell Stock
ImmuCell Revenue→
ImmuCell Stock
ImmuCell Net Income→
ImmuCell Stock
ImmuCell P/E→
ImmuCell Stock
ImmuCell P/S→
ImmuCell Stock
ImmuCell EBIT→
ImmuCell Stock
ImmuCell Dividend→
ImmuCell Stock
ImmuCell Directors Dealings→
ImmuCell Stock
ImmuCell Stocks→
ImmuCell Stock
ImmuCell Market capitalization→
ImmuCell Stock
ImmuCell Debt→
ImmuCell Stock
ImmuCell Liabilities→
ImmuCell Stock
ImmuCell Equity→
ImmuCell Stock
ImmuCell AAQS→
ImmuCell Stock
ImmuCell Employees→
ImmuCell Stock
ImmuCell ROE→
ImmuCell Stock
ImmuCell ROA→
ImmuCell Stock
ImmuCell ROCE→
ImmuCell Stock
ImmuCell News→
ImmuCell Stock
ImmuCell Analyst Price Targets→

Health Stocks

ImmuneeringImmix BiopharmaImmuneOncia TherapeuticsImmaticsImmuneOnco Biopharmaceuticals ShanghaiImexpharmImmunicImExHSImmunitybioImeik Technology Development CoImmuno-Biological Laboratories CoIMD International Medical Devices SpAAll Stocks A–Z →